Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice

Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice

Abstract Background The FDA-approved small-molecule drug ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib inhibits Bruton’s tyrosine kinase (BTK), a kinase involved in B cell receptor signaling. However, the potential regulation of neuroinfla...

Full description

Bibliographic Details
Main Authors: Hye Yeon Nam, Jin Han Nam, Gwangho Yoon, Ju-Young Lee, Youngpyo Nam, Hye-Jin Kang, Hyun-Ji Cho, Jeongyeon Kim, Hyang-Sook Hoe
Format: Article
Language:English
Published: BMC 2018-09-01
Series:Journal of Neuroinflammation
Subjects:
LPS
Neuroinflammation
STAT3
AKT
Microglia
Online Access:http://link.springer.com/article/10.1186/s12974-018-1308-0

Internet

http://link.springer.com/article/10.1186/s12974-018-1308-0

Similar Items